Press Releases

Jan 06, 2022

Imvaq Therapeutics signs a Service and Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

read more Imvaq Therapeutics signs a Service and Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

download PDF

Dec 17, 2021

ProBioGen's GlymaxX® Technology reaches Phase III Clinical Development

read more ProBioGen's GlymaxX® Technology reaches Phase III Clinical Development

download PDF

Nov 17, 2021

ProBioGen's GlymaxX® Technology made it again into Clinical Phase I

read more ProBioGen's GlymaxX® Technology made it again into Clinical Phase I

download PDF

Nov 03, 2021

PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development

read more PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development

download PDF

Sep 28, 2021

ProBioGen’s DirectedLuck™ Transposase Licensed by TOP15 Global BioPharma Company

read more ProBioGen’s DirectedLuck™ Transposase Licensed by TOP15 Global BioPharma Company

download PDF

Aug 12, 2021

Nobelpharma signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®

read more Nobelpharma signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®

download PDF

Jul 27, 2021

ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®

read more ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®

download PDF

Jul 13, 2021

Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line

read more Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line

download PDF

Jun 22, 2021

ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific

read more ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific

download PDF

Jun 09, 2021

City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

read more City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

download PDF

Page 3 of 11

ProBioGen News

Join our news and always be up-to-date.

Sign up